Abstract
The serendipitous discovery of ketamine’s antidepressant effects represents one of the major landmarks in neuropsychopharmacological research of the last 50 years. Ketamine provides an exciting challenge to traditional concepts of antidepressant drug therapy, producing rapid antidepressant effects seemingly without targeting monoaminergic pathways in the conventional way. In consequence, the advent of ketamine has spawned a plethora of neurobiological research into its putative mechanisms. Here, we provide a brief overview of current theories of antidepressant drug action including monoaminergic signaling, disinhibition of glutamatergic neurotransmission, neurotrophic and neuroplastic effects, and how these might relate to ketamine. Given that research into ketamine has not yet yielded new therapies beyond ketamine itself, current knowledge gaps and limitations of available studies are also discussed.
Introduction
Ketamine, synthesized in 1962 by the research team of Calvin Stevens, was the culmination of Parke-Davis’s drive to find a short-acting intravenous anesthetic with favorable cardiovascular and respiratory characteristics (). Ketamine replaced its congener phencyclidine (PCP), which, after a brief period of use as an anesthetic agent under the brand name Sernyl ®, had to be abandoned owing to high rates of postoperative dysphoria and hallucinations (). The distinctive state produced by ketamine — characterized by analgesia, catalepsy, and amnesia, while maintaining respiratory reflexes and hemodynamic stability — was first described by , who dubbed it “dissociative anesthesia.” Its wide therapeutic index makes ketamine an excellent agent for use in emergency medical practice, battlefield pain management, and, more generally, in resource-stripped settings such as the developing world. Ketamine remains on the most recent WHO Model List of Essential Medicines as an injectable general anesthetic ().
Ketamine burst on the scene of antidepressant psychopharmacology in 2000 with the publication of its first double-blind placebo-controlled trial in major depression. This pilot investigation of seven patients found significant improvements in mood within 72 h of a single subanesthetic dose of intravenous racemic ketamine hydrochloride (). A number of follow-up studies have confirmed the fast-onset antidepressant effects of ketamine infusions (; ; ,). Moreover, adjunctive intravenous ketamine has emerged as a powerful new treatment option for patients suffering from treatment-resistant depression (TRD; ; ). In the interim, variant forms of ketamine therapy including treatment with the S-enantiomer (i.e., S-ketamine) and administration via the nasal () and oral route () have also been demonstrated to confer rapid antidepressant benefit. Table 1 summarizes key studies of ketamine in depression.
TABLE 1
| Number of patients investigated | Study design | Route of administration | Patient characteristics | Results | References |
| 9 (2 drop-outs) | Randomized, double-blind study of single dose of ketamine hydrochloride (0.5 mg/kg); two treatment days, at least 1 week apart | Intravenous | Recurrent unipolar depression and bipolar depression; unmedicated patients | Significant improvement within 72 h after ketamine (HDRS) | |
| 18 (1 drop-out) | Randomized, placebo-controlled, double-blind crossover study of single dose of ketamine hydrochloride (0.5 mg/kg) | Intravenous | Major depressive disorder, recurrent, without psychotic features; unmedicated patients | Significant improvement within 110 min after ketamine which remained significant throughout the following week (HDRS) | |
| 10 | Repeated-dose open-label ketamine hydrochloride (0.5 mg/kg; six infusions over 12 days) | Intravenous | Medication free symptomatic patients suffering from treatment-resistant depression (patients excluded if they had lifetime history of psychotic symptoms or hypomania/mania) | The mean (SD) reduction in MADRS scores after sixth infusion was 85% (12%). | |
| 73 | Two-site, parallel-arm, randomized controlled trial of a single dose of ketamine hydrochloride (0.5 mg/kg) compared to active placebo (i.e., midazolam, 0.045 mg/kg) in a 2:1 ratio. | Intravenous | Treatment-resistant major depression (patients excluded if they had lifetime history of psychotic symptoms or bipolar disorder); unmedicated patients (with the exception of a stable dose of a non-benzodiazepine hypnotic). | Ketamine group showed greater improvement (MADRS score) than midazolam group 24 h after treatment | |
| 24 | Series of up to six infusions of ketamine hydrochloride (0.5 mg/kg) administered open-label three times weekly over a 12-day period. | Intravenous | Treatment-resistant major depression (patients excluded if they had lifetime history of psychotic symptoms or bipolar disorder); patients free of antidepressant medication during infusion period | Large mean decrease in MADRS score at 2 h after first ketamine infusion which was largely sustained for the duration of the infusion period. | |
| 18 | Randomized, placebo-controlled, double-blind, crossover, add-on study of ketamine hydrochloride (0.5 mg/kg) or placebo combined with lithium or valproate therapy on 2 test days 2 weeks apart | Intravenous | Treatment resistant bipolar I or II depression without psychotic features | Depressive symptoms significantly improved within 40 min in subjects receiving ketamine compared with placebo; improvement remained significant through day 3. | |
| 99 | Double-blind ketamine or placebo added to ongoing antidepressant therapy; patients randomly assigned to one of five study arms in a 1:1:1:1:1 fashion: single dose of ketamine 0.1 mg/kg (n = 18), 0.2 mg/kg (n = 20), 0.5 mg/kg (n = 22), 1.0 mg/kg (n = 20), and a single dose of midazolam 0.045 mg/kg (n = 19) | Intravenous | Treatment-resistant MDD (patients excluded if they had history of bipolar disorder, schizophrenia, or schizoaffective disorders, or any history of psychotic symptoms in current or previous depressive episodes) | Evidence for the efficacy of the 0.5 mg/kg and 1.0 mg/kg subanesthetic doses of IV ketamine, no clear or consistent evidence for clinically meaningful efficacy of lower doses | |
| 197 patients completed 28-day double-blind treatment phase. | Phase 3, double-blind, active-controlled, multicenter study of esketamine (56 and 84 mg versus placebo) | Intranasal | Treatment resistant moderate to severe MDD (key exclusion criteria: diagnosis of psychotic disorder, major depressive disorder with psychotic features, bipolar or related disorders, borderline, antisocial, histrionic, or narcissistic personality disorder) | Change in MADRS score with esketamine plus antidepressant significantly greater than with antidepressant plus placebo at day 28, clinically meaningful improvement observed in the esketamine plus antidepressant arm at earlier time points | |
| 41 | Randomized, double-blind, placebo-controlled, proof-of-concept trial; participants received either 1 mg/kg oral ketamine or placebo thrice weekly for 21 days | Oral | Treatment-resistant MDD (key exclusion criteria: psychotic disorder or psychotic symptoms, bipolar disorder) | Reduction in MADRS score on day 21 significantly greater in the ketamine group than in the control group. Six participants in ketamine group (27.3%) achieved remission compared with none of the controls. |
Overview of key studies of ketamine in depression.
From a neuroscience perspective, the uncanny rapidity of ketamine’s antidepressant action (often within a few hours) sets it apart from conventional antidepressants, providing a new window on the neurobiology of the antidepressant response with exciting possibilities for translational and, maybe even more interesting, reverse translational research. The purpose of this mini-review is, therefore, to provide an overview of current thinking on ketamine’s putative mechanisms of action within the context of antidepressant drug discovery and development.
Monoamine Mechanisms
The short history of the development of antidepressant drugs is riddled with accidental yet transformative discoveries. At the risk of recounting well-known facts, here is a summary of the milestones: Iproniazid, initially developed and marketed by Hoffmann La-Roche as an antibiotic to treat tuberculosis (Marsilid ®), was serendipitously identified as possessing antidepressant characteristics (; ). A connection was quickly made with iproniazid’s strong inhibitory effect on monoamine oxidase (MAO), paving the way for the targeted development of other, more refined, and ultimately safer MAO inhibitors, which are still widely prescribed today (e.g., ). The antidepressant activity of imipramine, the first tricyclic antidepressant, was recognized almost coevally with the discovery of iproniazid’s antidepressant properties (). Inhibition of the reuptake of biogenic amines was swiftly identified as the primary molecular mechanism of tricyclics (; , ; ). The observation that blood-pressure lowering drug reserpine may precipitate depression () provided further support for a link between brain levels of biogenic amines and mood states. Taken together, and in historical perspective, this “monoamine hypothesis” of depression has proven incredibly useful in the development of newer classes of antidepressants (such as selective serotonin reuptake inhibitors, noradrenaline reuptake inhibitors, dual reuptake inhibitors, etc.) that are usually superior to the older compounds with comparable efficacy yet fewer side effects and a greater therapeutic index. Nevertheless, the clinical limitations of monoamine-based agents, in particular relatively high rates of non-response and even resistance to treatment, have long led to calls to focus more research on alternative mechanisms ().
An obvious conceptual problem with the monoamine hypothesis lies in the fact that changes in neurotransmitter concentrations (along with the onset of typical side effects) occur within a few hours while conventional antidepressants typically require several days to weeks to take effect. Neurobiological research into the mechanisms underpinning the antidepressant response has therefore pivoted to longer-term adaptive changes downstream of the acute effects on biogenic amines.
Ketamine’s principal pharmacological action is as an N-methyl-D-aspartate (NMDA) receptor antagonist. However, in a manner somewhat reminiscent of clozapine, ketamine is a “dirty” drug. Multiple off-target effects including on monoamine systems need to be considered. In vitro, ketamine displays affinity to dopamine D2 and serotonin 5-HT2 receptors in the same range as its affinity for the NMDA receptor (). It has also been reported that ketamine inhibits monoamine transporters in cultured cells () and blocks the uptake of [3H]-dopamine into rat striatal synaptosomes ().
Repeated ketamine injections increase the firing rate of norepinephrine neurons in the locus coeruleus and of dopaminergic neurons in the ventral tegmental area in rats (). Microdialysis studies have demonstrated increased serotonin release by ketamine in the rodent prefrontal cortex (; ). Several groups have found that serotonin depletion abrogates the antidepressive-like effects of ketamine in the forced swim test (; ; ; ). Even so, measurable occupancy of the serotonin transporter in vivo was not detectable by positron emission tomography in twelve healthy human subjects after infusion of an antidepressant dose of ketamine ().
While the available literature indicates that ketamine leads to increased dopamine levels in frontal cortex, striatum, and nucleus accumbens in rodents, the picture is less clear for the primate and human brain, given methodological issues and the scant available literature (). From a clinical perspective, the fact that haloperidol is able to ameliorate ketamine-induced psychosis argues for a role of dopaminergic pathways in ketamine’s psychotropic effects ().
Ketamine and the Glutamatergic System
Racemic ketamine acts as a non-competitive NMDA receptor antagonist (Figure 1A). It is believed that the dissociative and psychotomimetic effects of PCP and ketamine relate directly to the affinity of these molecules to the NMDA receptor. Based on displacement binding studies with [3H]-MK801 as the marker ligand, S-ketamine exhibits an approximately three- to fourfold higher affinity to the NMDA receptor than R-ketamine (). The pharmacokinetic profiles of racemic ketamine and its two enantiomers do not differ significantly in humans (). Serum ketamine concentrations at the point of regaining consciousness and orientation during the course of experimental anesthesia of human volunteers indicate an S:R ketamine isomer potency ratio of 4:1. Similarly, S-ketamine has an approximately three- to fivefold greater ability to impair psychomotor function than R-ketamine (). The available literature, though scant, seems to suggests that, in humans, subanesthetic doses of R-ketamine lack the dissociative potential of racemic ketamine (; ).
FIGURE 1
It is tempting to speculate that the dissociative and the antidepressant effects of ketamine might be separable. In the context of double-blind placebo-controlled drug testing, this is a complex issue because questions around functional unblinding due to ketamine’s dissociative effects and the potential use of active comparators have to be considered (). At least so far, the bulk of the available clinical evidence seems to favor an association between racemic ketamine’s hallucinogenic/dissociative and antidepressant effects ().
While clinical research into a possible role for R-ketamine in depression is still in its infancy, sufficient data has already accrued to recommend the use of S-ketamine. Intravenous S-ketamine has been shown to produce rapid onset of robust antidepressant effects in patients with TRD after a 40-min infusion (). Further, there is meta-analytical evidence for the adjunctive intranasal use of S-ketamine in TRD and in depressed patients with acute suicidality (). Moreover, a recent randomized double-blind head-to-head comparison of intravenous S-ketamine (0.25 mg/kg) and racemic ketamine (0.5 mg/kg) as adjunctive therapy in TRD confirmed non-inferiority of S-ketamine ().
N-methyl-D-aspartate receptor blockade may augment glutamatergic outflow, e.g., in the prefrontal cortex. Indeed, one plausible mechanism of this seemingly paradoxical effect is that ketamine, when administered in a subanesthetic dose, blocks NMDA receptors on γ-aminobutyric acid interneurons, thereby increasing presynaptic release of glutamate (; ). According to this “disinhibition hypothesis” (Figure 1B), downstream activation of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors in mood-regulating synapses is believed to play a crucial role in mediating ketamine’s rapid antidepressant response as evidenced by the fact that pre-treatment with NBQX, an AMPA receptor antagonist, attenuates the behavioral effects of ketamine in experimental mice and rats (; ). It thus appears that, ultimately, ketamine produces increased glutamatergic throughput of AMPA receptors, as compared to NMDA receptors, triggering rapid downstream changes on the molecular, structural, and network levels (Figure 1B; ; ; ).
While clinical research has, so far, focused primarily on the S-ketamine stereoisomer, it has been hypothesized, based on behavioral studies in experimental mice, that R-ketamine should show the greater antidepressant potency (; ). To our knowledge, there is currently only one small pilot trial that has investigated the effects of R-ketamine in major depression (). That open-label study of seven patients reported a significant decrease in Montgomery-Åsberg Depression Rating Scale scores within 24 h of a single intravenous infusion of R-ketamine (0.5 mg/kg).
There is extensive metabolism of ketamine stereoisomers via cytochrome P450 enzymes producing a broad array of catabolites including norketamine, hydroxyketamines, dehydronorketamine, and the hydroxynorketamines (; ). In particular, potent antidepressant properties have been ascribed to the (2R,6R)-hydroxynorketamine [(2R,6R)-HNK] metabolite (Figure 1A), which is exclusively derived from R-ketamine (). Mechanistically, (2R,6R)-HNK acts through AMPA receptor-mediated mechanisms, with the AMPA receptor antagonist NBQX reversing its antidepressant-like effects (). Moreover, (2R,6R)-HNK recapitulates key downstream events observed in the rodent brain in response to ketamine such as increased neurotrophic signaling and rapid dendritic and synaptic plasticity (; ).
Neurotrophic Signaling, Neuroplasticity, and Stress
Profound structural changes such as neuronal atrophy, loss of synapses, and a decrease in hippocampal neurogenesis reflect the deleterious effects of stress, stress hormones, and major depression on the brain (). Brain-derived neurotrophic factor (BDNF)/tropomyosin receptor kinase B (TrkB) signaling is of crucial importance to neuronal plasticity, morphogenesis, and survival (). Numerous pre-clinical studies have connected stress and an excess of corticosteroids with reduced BDNF signaling in depression-related brain areas (; ; ; ). Conversely, bilateral infusion of BDNF into the hippocampal dentate gyrus has been shown to produce antidepressant-like effects in behavioral models of depression (). Antidepressant interventions such as electroconvulsive therapy (), physical activity (), and conventional antidepressant pharmacotherapy () have all been linked with a rise in brain BDNF levels. Likewise, ketamine administration has been shown to raise BDNF mRNA and protein levels in hippocampus (). BDNF signaling seems to be central to ketamine’s distinct antidepressant activity because ketamine fails to produce rapid antidepressant-like effects in either BDNF or TrkB conditional knockout mice (). Quite unexpectedly, some very recent research has demonstrated an exciting new mode of action of several antidepressants, including ketamine, beyond increasing BDNF concentrations, namely, to directly bind to TrkB (). Antidepressant binding to TrkB could then facilitate BDNF action and the attendant cellular as well as structural plasticity (). An important intracellular signaling pathway activated in response to ketamine is the mammalian target of rapamycin pathway. Activation of this pathway promotes rapid synaptic plasticicity with increased synaptic signaling proteins and increased number and function of synapses (). In this context, and given that the anti-dementia drug memantine, which shares with ketamine the property of non-competitive NMDA antagonism, is widely prescribed in Alzheimer’s disease, it may be worthwhile to assess the effects of ketamine in patients with dementia ().
So far, few studies have investigated the effects of ketamine on hippocampal neurogenesis (). It has been reported that ketamine increases cell proliferation in the hippocampal dentate gyrus of rats showing a depressive-like phenotype (). However, since neurogenesis is a multi-step process that unfolds over several weeks (), it is unlikely that an overall increase in neurogenesis explains ketamine’s rapid antidepressant effects. Still, increased recruitment of adult-born neurons into hippocampal circuitry (i.e., an acceleration in the final stages of neurogenesis) in response to ketamine is an obvious possibility, especially considering the importance of these immature cells for shaping memory processes ().
Open Questions and Outlook
An honest appraisal of where the field stands today must acknowledge the fact that, so far, “decades of ‘murinization”’ have contributed relatively little to antidepressant development (). From the sole perspective of drug discovery, the poor predictability of antidepressant efficacy based on behavioral assays in rodents is probably chief among today’s challenges. On the other hand, it should be noted that the concept of NMDA antagonism in the treatment of depression was developed against a rich backdrop of experimental research (reviewed in ), demonstrating, among other things, that chronic administration of desipramine inhibits glutamatergic neurotransmission at NMDA receptors (), and that both conventional antidepressants and electroconvulsive therapy alter the ligand-binding properties of the NMDA receptor complex (, ). Given the short nature of this mini-review, the considerable body of preclinical evidence demonstrating ketamine’s antidepressant activity in rodent models of depression has been largely passed over. For a detailed overview of this subject, the reader is referred to and .
How will the field evolve in the future? As a logical next step, the R-ketamine enantiomer is currently in the early stages of clinical development. Moreover, certain ketamine metabolites may hold promise as possessing equal antidepressant efficacy to the racemic parent molecule, possibly with fewer side effects, especially (2R,6R)-HNK. From a broader view, however, the prospect of discovering other molecules, not directly related to ketamine itself but tapping into the same neurobiological mechanisms, remains uncertain, at least for the time being. So far, the principle of NMDA antagonism has, unfortunately, not translated into tangible new drugs. Also, side-effects beyond psychotic symptoms have to be considered. Merck & Co’s dizocilpine (commonly referred to as MK-801 in the lab), a strong NMDA receptor antagonist, was shown to produce acute pathomorphological lesions in specific populations of neurons when administered acutely to adult rats in comparatively low doses (). MK-801 is no longer in active clinical development for this reason. Similar evidence of neurotoxicity (the eponymous “Olney’s” lesions) has also been observed in experimental rodents after ketamine and PCP (reviewed in ) and, more worryingly, in human ketamine addicts (). Given these findings, it will be important, from a safety standpoint, to monitor the long-term effects of NMDA antagonist therapy (including with ketamine and S-ketamine) on brain structure and patients’ cognitive trajectories.
Moving beyond neurotoxicity, which may represent a class effect, investigations of NMDA receptor antagonists other than ketamine in depression have, so far, failed to produce clinically relevant outcomes. Memantine proved ineffective as an antidepressant in two double-blind placebo-controlled trials (; ). Similarly, rislenemdaz (also known as MK-0657), an NR2B subunit-specific NMDA receptor antagonist, failed to produce antidepressant effects in TRD, either when used as a monotherapy or in conjunction with other antidepressants (; ). Lanicemine, an NMDA blocker with low rates of associated psychotomimetic effects, does not come near to replicating ketamine’s antidepressant effects (; ). More recently, three phase-III clinical trials of rapastinel, an NMDA receptor modulator with glycine-site partial agonist features, also failed to demonstrate antidepressant effects (). This outcome is sobering, given that pre-clinical research had demonstrated antidepressant-like effects of rapastinel in mice and rats (; ).
The possibility of still other modes of action should also not be overlooked. It has long been known that ketamine possesses certain anti-inflammatory properties, which may especially benefit patients undergoing major surgery or septic patients requiring sedation (; ). Intriguingly, lipopolysaccharide-induced sickness behavior in mice can be blocked by ketamine (). Moreover, the antidepressant effects of the two ketamine enantiomers in the chronic social defeat stress model of depression have been linked with restoration of gut microbiota in mice ().
Opioid effects have also been implicated in ketamine’s clinical profile. Both S- and R-ketamine bind to and activate mu and kappa opioid receptors (). Further, it has recently been reported that naltrexone blocks the antidepressant effects of ketamine in depressed patients ().
In the aggregate, ketamine represents the first major breakthrough in antidepressant development in the last half-century. As described above, it engages novel mechanisms beyond monoaminergic neurotransmission, resulting in a much faster onset of action than conventional monoamine-based therapeutics. Although much remains to be elucidated, the advent of ketamine signals exciting new opportunities to extend and refine our knowledge of the neurobiological mechanisms underlying the antidepressant response. Given the accruing evidence of ketamine’s therapeutic effects in TRD, it seems that the time has arrived to assign a central position to ketamine as an augmentation in the treatment algorithms for TRD patients.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Author contributions
GK drafted the manuscript with substantive input from all authors. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors are conducting a study of oral ketamine in TRD funded by Ketabon GmbH. ES serves on advisory boards of Janssen.
References
1
aan het RotM.CollinsK. A.MurroughJ. W.PerezA. M.ReichD. L.CharneyD. S.et al (2010). Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.Biol. Psychiatry67139–145. 10.1016/j.biopsych.2009.08.038
2
AgoY.TanabeW.HiguchiM.TsukadaS.TanakaT.YamaguchiT.et al (2019). (R)-Ketamine induces a greater increase in prefrontal 5-HT Release than (S)-Ketamine and ketamine metabolites via an AMPA Receptor-Independent Mechanism.Int. J. Neuropsychopharmacol.22665–674. 10.1093/ijnp/pyz041
3
AnackerC.HenR. (2017). Adult hippocampal neurogenesis and cognitive flexibility - linking memory and mood.Nat. Rev. Neurosci.18335–346. 10.1038/nrn.2017.45
4
AutryA. E.AdachiM.NosyrevaE.NaE. S.LosM. F.ChengP. F.et al (2011). NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.Nature47591–95. 10.1038/nature10130
5
AxelrodJ.WhitbyL. G.HerttingG. (1961). Effect of psychotropic drugs on the uptake of H3-norepinephrine by tissues.Science133383–384. 10.1126/science.133.3450.383
6
BallardE. D.ZarateC. A.Jr. (2020). The role of dissociation in ketamine’s antidepressant effects.Nat. Commun.11:6431. 10.1038/s41467-020-20190-4
7
BermanR. M.CappielloA.AnandA.OrenD. A.HeningerG. R.CharneyD. S.et al (2000). Antidepressant effects of ketamine in depressed patients.Biol. Psychiatry47351–354. 10.1016/s0006-3223(99)00230-9
8
BertonO.NestlerE. (2006). New approaches to antidepressant drug discovery: beyond monoamines.Nat. Rev. Neurosci.7137–151. 10.1038/nrn1846
9
BonaventuraJ.LamS.CarltonM.BoehmM. A.GomezJ. L.SolísO.et al (2021). Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability.Mol. Psychiatry [Epub Online ahead of print]. 10.1038/s41380-021-01093-2
10
BurgdorfJ.ZhangX. L.NicholsonK. L.BalsterR. L.LeanderJ. D.StantonP. K.et al (2013). GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.Neuropsychopharmacology38729–742. 10.1038/npp.2012.246
11
CarlssonA.FuxeK.HambergerB.LindqvistM. (1966). Biochemical and histochemical studies on the effects of imipramine-like drugs and (+)-amphetamine on central and peripheral catecholamine neurons.Acta Physiol. Scand.67481–497. 10.1111/j.1748-1716.1966.tb03334.x
12
CarlssonA.FuxeK.UngerstedtU. (1968). The effect of imipramine on central 5-hydroxytryptamine neurons.J. Pharm. Pharmacol.20150–151. 10.1111/j.2042-7158.1968.tb09706.x
13
CasarottoP. C.GirychM.FredS. M.KovalevaV.MolinerR.EnkaviG.et al (2021). Antidepressant drugs act by directly binding to TRKB neurotrophin receptors.Cell1841299–1313. 10.1016/j.cell.2021.01.034
14
ChoiM.LeeS. H.ParkM. H.KimY. S.SonH. (2017). Ketamine induces brain-derived neurotrophic factor expression via phosphorylation of histone deacetylase 5 in rats.Biochem. Biophys. Res. Commun.489420–425. 10.1016/j.bbrc.2017.05.157
15
ContiA. C.CryanJ. F.DalviA.LuckiI.BlendyJ. A. (2002). cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs.J. Neurosci.223262–3268. 10.1523/jneurosci.22-08-03262.2002
16
Correia-MeloF. S.LealG. C.VieiraF.Jesus-NunesA. P.MelloR. P.MagnavitaG.et al (2020). Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study.J. Affect Disord.264527–534. 10.1016/j.jad.2019.11.086
17
CorssenG.DominoE. F. (1965). Dissociative Anesthesia: Further Pharmacologic Studies and First Clinical Experience with the Phencyclidine Derivative CI-581.Anesth Analg.4529–40. 10.1213/00000539-196601000-00007
18
DestaZ.MoaddelR.OgburnE. T.XuC.RamamoorthyA.VenkataS. L.et al (2012). Stereoselective and regiospecific hydroxylation of ketamine and norketamine.Xenobiotica421076–1087. 10.3109/00498254.2012.685777
19
deVerteuilR. L.LehmannH. E. (1958). Therapeutic Trial of Iproniazid (Marsilid) in depressed and apathetic patients.Can. Med. Assoc. J.78131–133.
20
DeyamaS.DumanR. S. (2020). Neurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine.Pharmacol. Biochem. Behav.188:172837. 10.1016/j.pbb.2019.172837
21
DiazgranadosN.IbrahimL.BrutscheN. E.NewbergA.KronsteinP.KhalifeS.et al (2010). A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.Arch. Gen. Psychiatry67793–802. 10.1001/archgenpsychiatry.2010.90
22
DomanyY.Bleich-CohenM.TarraschR.MeidanR.Litvak-LazarO.StopplemanN.et al (2019). Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study.Br. J. Psychiatry21420–26. 10.1192/bjp.2018.196
23
du JardinK. G.LiebenbergN.MüllerH. K.ElfvingB.SanchezC.WegenerG. (2016). Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression.Psychopharmacology2332813–2825. 10.1007/s00213-016-4327-5
24
DumanR. S.AghajanianG. K.SanacoraG.KrystalJ. H. (2016). Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat. Med.22, 238–249. 10.1038/nm.4050
25
EllisonG. (1995). The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias.Brain Res. Brain Res. Rev.20250–267. 10.1016/0165-0173(94)00014-g
26
FavaM.FreemanM. P.FlynnM.JudgeH.HoeppnerB. B.CusinC.et al (2020). Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol. Psychiatry25, 1592–1603. 10.1038/s41380-018-0256-5
27
FukumotoK.IijimaM.ChakiS. (2015). The antidepressant effects of an mGlu2/3 receptor antagonist and ketamine require AMPA receptor stimulation in the mPFC and subsequent activation of the 5-HT neurons in the DRN.Neuropsychopharmacology411046–1056. 10.1038/npp.2015.233
28
FuxeK.UngerstedtU. (1968). Histochemical studies on the effect of (+)-amphetamine, drugs of the imipramine group and tryptamine on central catecholamine and 5-hydroxytryptamine neurons after intraventricular injection of catecholamines and 5-hydroxytryptamine.Eur. J. Pharmacol.4135–144. 10.1016/0014-2999(68)90169-6
29
GianniniA. J.UnderwoodN. A.CondonM. (2000). Acute ketamine intoxication treated by haloperidol: a preliminary study.Am. J. Ther.7389–391. 10.1097/00045391-200007060-00008
30
GigliucciV.O’DowdG.CaseyS.EganD.GibneyS.HarkinA. (2013). Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism.Psychopharmacology228157–166. 10.1007/s00213-013-3024-x
31
HarrisT. H. (1957). Depression induced by Rauwolfia compounds.Am. J. Psychiat.113:950. 10.1176/ajp.113.10.950
32
HenterI. D.ParkL. T.ZarateC. A.Jr. (2021). Novel glutamatergic modulators for the treatment of mood disorders: current status.CNS Drugs35527–543. 10.1007/s40263-021-00816-x
33
HolsboerF. (2014). Redesigning antidepressant drug discovery.Dialogues Clin. Neurosci.165–7. 10.31887/dcns.2014.16.1/fholsboer
34
HuangE. J.ReichardtL. F. (2001). Neurotrophins: roles in neuronal development and function.Annu. Rev. Neurosci.24677–736. 10.1146/annurev.neuro.24.1.677
35
IbrahimL.Diaz GranadosN.JolkovskyL.BrutscheN.LuckenbaughD. A.HerringW. J.et al (2012). A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder.J. Clin. Psychopharmacol.32551–557. 10.1097/JCP.0b013e31825d70d6
36
IroC. M.HamatiR.El MansariM.BlierP. (2021). Repeated but not single administration of ketamine prolongs increases of the firing activity of norepinephrine and dopamine neurons.Int. J. Neuropsychopharmacol.24570–579. 10.1093/ijnp/pyab010
37
JourdiH.HsuY. T.ZhouM.QinQ.BiX.BaudryM. (2009). Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation.J. Neurosci.298688–8697. 10.1523/JNEUROSCI.6078-08.2009
38
KapurS.SeemanP. (2002). NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors—implications for models of schizophrenia.Mol. Psychiatry7837–844. 10.1038/sj.mp.4001093
39
KawasakiT.OgataM.KawasakiC.OgataJ.InoueY.ShigematsuA. (1999). Ketamine suppresses proinflammatory cytokine production in human whole blood in vitro.Anesth. Analg.89665–669. 10.1213/00000539-199909000-00024
40
KeitaH.LecharnyJ. B.HenzelD.DesmontsJ. M.MantzJ. (1996). Is inhibition of dopamine uptake relevant to the hypnotic action of i.v. anaesthetics?Br. J. Anaesth.77254–256. 10.1093/bja/77.2.254
41
KempermannG.JessbergerS.SteinerB.KronenbergG. (2004). Milestones of neuronal development in the adult hippocampus.Trends Neurosci.27447–452. 10.1016/j.tins.2004.05.013
42
KharaschE. D.LabrooR. (1992). Metabolism of ketamine stereoisomers by human liver microsomes.Anesthesiology771201–1207. 10.1097/00000542-199212000-00022
43
KoikeH.ChakiS. (2014). Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats.Behav. Brain Res.271111–115. 10.1016/j.bbr.2014.05.065
44
KokkinouM.AshokA. H.HowesO. D. (2018). The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders.Mol. Psychiatry2359–69. 10.1038/mp.2017.190
45
KuhnR. (1957). Treatment of depressive states with an iminodibenzyl derivative (G 22355).Schweiz. Med. Wochenschr.871135–1140.
46
LealG. C.BandeiraI. D.Correia-MeloF. S.TellesM.MelloR. P.VieiraF.et al (2021). Intravenous arketamine for treatment-resistant depression: open-label pilot study.Eur. Arch. Psychiatry Clin. Neurosci.271577–582. 10.1007/s00406-020-01110-5
47
LiN.LeeB.LiuR. J.BanasrM.DwyerJ. M.IwataM.et al (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.Science329959–964. 10.1126/science.1190287
48
LoomerH. P.SaundersJ. C.KlineN. S. (1957). A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer.Psychiatr. Res. Rep. Am. Psychiatr. Assoc.8129–141.
49
López-GilX.Jiménez-SánchezL.CampaL.CastroE.FragoC.AdellA. (2019). Role of Serotonin and Noradrenaline in the Rapid Antidepressant Action of Ketamine.ACS Chem. Neurosci.103318–3326. 10.1021/acschemneuro.9b00288
50
MaengS.ZarateC. A.Jr.DuJ.SchloesserR. J.McCammonJ.ChenG.et al (2008). Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.Biol. Psychiatry63349–352. 10.1016/j.biopsych.2007.05.028
51
MathaiD. S.MeyerM. J.StorchE. A.KostenT. R. (2020). The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: a systematic review.J. Affect Disord.264123–129. 10.1016/j.jad.2019.12.023
52
MeyerJ. S.GreifensteinF.DevaultM. (1959). A new drug causing symptoms of sensory deprivation.J. Nerv. Ment. Dis.12954–61. 10.1097/00005053-195907000-00006
53
MichaëlssonH.AnderssonM.SvenssonJ.KarlssonL.EhnJ.CulleyG.et al (2019). The novel antidepressant ketamine enhances dentate gyrus proliferation with no effects on synaptic plasticity or hippocampal function in depressive-like rats.Acta Physiol. (Oxf)225:e13211. 10.1111/apha.13211
54
MionG. (2017). History of anaesthesia: the ketamine story - past, present and future.Eur. J. Anaesthesiol.34571–575. 10.1097/EJA.0000000000000638
55
MjellemN.LundA.HoleK. (1993). Reduction of NMDA-induced behaviour after acute and chronic administration of desipramine in mice.Neuropharmacology32591–595. 10.1016/0028-3908(93)90055-8
56
MoaddelR.AbdrakhmanovaG.KozakJ.JozwiakK.TollL.JimenezL.et al (2013). Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in alpha7 nicotinic acetylcholine receptors.Eur. J. Pharmacol.698228–234. 10.1016/j.ejphar.2012.11.023
57
MoghaddamB.AdamsB.VermaA.DalyD. (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.J. Neurosci.172921–2927. 10.1523/JNEUROSCI.17-08-02921.1997
58
MurroughJ. W.IosifescuD. V.ChangL. C.Al JurdiR. K.GreenC. E.PerezA. M.et al (2013a). Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.Am. J. Psychiatry1701134–1142. 10.1176/appi.ajp.2013.13030392
59
MurroughJ. W.PerezA. M.PillemerS.SternJ.ParidesM. K.aan het RotM.et al (2013b). Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.Biol. Psychiatry74250–256. 10.1016/j.biopsych.2012.06.022
60
NibuyaM.MorinobuS.DumanR. S. (1995). Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments.J. Neurosci.157539–7547. 10.1523/JNEUROSCI.15-11-07539.1995
61
NishimuraM.SatoK.OkadaT.YoshiyaI.SchlossP.ShimadaS.et al (1998). Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells.Anesthesiology88768–774. 10.1097/00000542-199803000-00029
62
OhH.PiantadosiS. C.RoccoB. R.LewisD. A.WatkinsS. C.SibilleE. (2019). The role of dendritic brain-derived neurotrophic factor transcripts on altered inhibitory circuitry in depression.Biol. Psychiatry85517–526. 10.1016/j.biopsych.2018.09.026
63
OlneyJ. W.LabruyereJ.PriceM. T. (1989). Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs.Science2441360–1362. 10.1126/science.2660263
64
PapakostasG. I.SalloumN. C.HockR. S.JhaM. K.MurroughJ. W.MathewS. J.et al (2020). Efficacy of esketamine augmentation in major depressive disorder: a meta-analysis.J. Clin. Psychiatry81:19r12889. 10.4088/JCP.19r12889
65
PaulI. A.LayerR. T.SkolnickP.NowakG. (1993). Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine.Eur. J. Pharmacol.247305–311. 10.1016/0922-4106(93)90199-J
66
PaulI. A.NowakG.LayerR. T.PopikP.SkolnickP. (1994). Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments.J. Pharmacol. Exp. Ther.26995–102.
67
PhamT. H.Mendez-DavidI.DefaixC.GuiardB. P.TritschlerL.DavidD. J.et al (2017). Ketamine treatment involves medial prefrontal cortex serotonin to induce a rapid antidepressant-like activity in BALB/cJ mice.Neuropharmacology112198–209. 10.1016/j.neuropharm.2016.05.010
68
PolisA. J.FitzgeraldP. J.HaleP. J.WatsonB. O. (2019). Rodent ketamine depression-related research: finding patterns in a literature of variability.Behav. Brain Res.376:112153. 10.1016/j.bbr.2019.112153
69
PopovaV.DalyE. J.TrivediM.CooperK.LaneR.LimP.et al (2019). Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study.Am. J. Psychiatry176428–438. 10.1176/appi.ajp.2019.19020172
70
PothulaS.KatoT.LiuR. J.WuM.GerhardD.ShinoharaR.et al (2020). Cell-type specific modulation of NMDA receptors triggers antidepressant actions.Mol. Psychiatry [Epub Online ahead of print]. 10.1038/s41380-020-0796-3
71
Rincón-CortésM.GraceA. A. (2020). Antidepressant effects of ketamine on depression-related phenotypes and dopamine dysfunction in rodent models of stress.Behav. Brain Res.379:112367. 10.1016/j.bbr.2019.112367
72
SanacoraG.JohnsonM. R.KhanA.AtkinsonS. D.RiesenbergR. R.SchronenJ. P.et al (2017). Adjunctive Lanicemine (AZD6765) in patients with major depressive disorder and history of inadequate response to antidepressants: a randomized, placebo-controlled study.Neuropsychopharmacology42844–853. 10.1038/npp.2016.224
73
SchaafM. J.De KloetE. R.VreugdenhilE. (2000). Corticosterone effects on BDNF expression in the hippocampus. Implications for memory formation.Stress3201–208. 10.3109/10253890009001124
74
ShinoharaR.AghajanianG. K.AbdallahC. G. (2020). Neurobiology of the rapid-acting antidepressant effects of ketamine: impact and opportunities.Biol. Psychiatry9085–95. 10.1016/j.biopsych.2020.12.006
75
ShirayamaY.ChenA. C.NakagawaS.RussellD. S.DumanR. S. (2002). Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression.J. Neurosci.223251–3261. 10.1523/JNEUROSCI.22-08-03251.2002
76
SinghJ. B.FedgchinM.DalyE.XiL.MelmanC.De BrueckerG.et al (2016). Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study.Biol. Psychiatry80424–431. 10.1016/j.biopsych.2015.10.018
77
SkolnickP.LayerR. T.PopikP.NowakG.PaulI. A.TrullasR. (1996). Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry29, 23–26. 10.1055/s-2007-979537
78
SleimanS. F.HenryJ.Al-HaddadR.El HayekL.Abou HaidarE.StringerT.et al (2016). Exercise promotes the expression of brain derived neurotrophic factor (BDNF) through the action of the ketone body β-hydroxybutyrate. Elife5:e15092. 10.7554/eLife.15092
79
SmalheiserN. R. (2019). Ketamine: a neglected therapy for Alzheimer disease.Front. Aging Neurosci.11:186. 10.3389/fnagi.2019.00186
80
SmithE. G.DeligiannidisK. M.UlbrichtC. M.LandolinC. S.PatelJ. K.RothschildA. J. (2013). Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial.J. Clin. Psychiatry74966–973. 10.4088/JCP.12m08252
81
SmithM. A.MakinoS.KvetnanskyR.PostR. M. (1995). Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus.J. Neurosci.151768–1777. 10.1523/JNEUROSCI.15-03-01768.1995
82
SpiesM.JamesG. M.Berroterán-InfanteN.IbeschitzH.KranzG. S.UnterholznerJ.et al (2018). Assessment of ketamine binding of the serotonin transporter in humans with positron emission tomography.Int. J. Neuropsychopharmacol.21145–153. 10.1093/ijnp/pyx085
83
StefanisC. N.AlevizosB. H.PapadimitriouG. N. (1982). Antidepressant effect of Ro 11-1163, a new MAO inhibitor.Int. Pharmacopsychiatry1743–48. 10.1159/000468556
84
VollenweiderF. X.LeendersK. L.OyeI.HellD.AngstJ. (1997). Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET).Eur. Neuropsychopharmacol.725–38. 10.1016/S0924-977X(96)00042-9
85
VollmayrB.FaustH.LewickaS.HennF. A. (2000). Brain-derived-neurotrophic-factor (BDNF) stress response in rats bred for learned helplessness.Mol. Psychiatry6471–474. 10.1038/sj.mp.4000907
86
WalkerA. K.BudacD. P.BisulcoS.LeeA. W.SmithR. A.BeendersB.et al (2013). NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice.Neuropsychopharmacology381609–1616. 10.1038/npp.2013.71
87
WangC.ZhengD.XuJ.LamW.YewD. T. (2013). Brain damages in ketamine addicts as revealed by magnetic resonance imaging.Front. Neuroanat.7:23. 10.3389/fnana.2013.00023
88
WeltersI. D.FeurerM. K.PreissV.MüllerM.ScholzS.KwapiszM.et al (2011). Continuous S-(+)-ketamine administration during elective coronary artery bypass graft surgery attenuates pro-inflammatory cytokine response during and after cardiopulmonary bypass.Br. J. Anaesth.106172–179. 10.1093/bja/aeq341
89
WhiteP. F.SchüttlerJ.ShaferA.StanskiD. R.HoraiY.TrevorA. J. (1985). Comparative pharmacology of the ketamine isomers.Br. J. Anesthesiol.57197–203. 10.1093/bja/57.2.197
90
WilliamsN. R.HeifetsB. D.BlaseyC.SudheimerK.PannuJ.PankowH.et al (2018). Attenuation of antidepressant effects of ketamine by opioid receptor antagonism.Am. J. Psychiatry1751205–1215. 10.1176/appi.ajp.2018.18020138
91
World Health Organization [WHO] (2019). Model List of Essential Medicines. Available Online at: https://www.who.int/publications/i/item/WHOMVPEMPIAU2019.06(accessed April 1, 2021).
92
YangB.ZhangJ. C.HanM.YaoW.YangC.RenQ.et al (2016). Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression.Psychopharmacology (Berl)2333647–3657. 10.1007/s00213-016-4399-2
93
YangC.QuY.FujitaY.RenQ.MaM.DongC.et al (2017). Possible role of the gut microbiota-brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model.Transl. Psychiatry7:1294. 10.1038/s41398-017-0031-4
94
YangC.ShirayamaY.ZhangJ. C.RenQ.YaoW.MaM.et al (2015). R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects.Transl. Psychiatry5:e632. 10.1038/tp.2015.136
95
ZanosP.MoaddelR.MorrisP. J.GeorgiouP.FischellJ.ElmerG. I.et al (2016). NMDAR inhibition-independent antidepressant actions of ketamine metabolites.Nature533481–486. 10.1038/nature17998
96
ZarateC. A.Jr.MathewsD.IbrahimL.ChavesJ. F.MarquardtC.UkohI.et al (2013). A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression.Biol. Psychiatry74257–264. 10.1016/j.biopsych.2012.10.019
97
ZarateC. A.Jr.SinghJ. B.CarlsonP. J.BrutscheN. E.AmeliR.LuckenbaughD. A.et al (2006a). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.Arch. Gen. Psychiatry63856–864. 10.1001/archpsyc.63.8.856
98
ZarateC. A.Jr.SinghJ. B.QuirozJ. A.De JesusG.DenicoffK. K.LuckenbaughD. A.et al (2006b). A double-blind, placebo-controlled study of memantine in the treatment of major depression.Am. J. Psychiatry163153–155. 10.1176/appi.ajp.163.1.153
Summary
Keywords
depression, antidepressant, treatment-resistant depression, ketamine, BDNF, neurogenesis, monoamines, glutamate
Citation
Colla M, Scheerer H, Weidt S, Seifritz E and Kronenberg G (2021) Novel Insights Into the Neurobiology of the Antidepressant Response From Ketamine Research: A Mini Review. Front. Behav. Neurosci. 15:759466. doi: 10.3389/fnbeh.2021.759466
Received
16 August 2021
Accepted
28 October 2021
Published
03 December 2021
Volume
15 - 2021
Edited by
Matthew O. Parker, University of Portsmouth, United Kingdom
Reviewed by
Juan Francisco Rodríguez-Landa, Universidad Veracruzana, Mexico; Darcy Litteljohn, Independent Researcher, Toronto, ON, Canada
Updates
Copyright
© 2021 Colla, Scheerer, Weidt, Seifritz and Kronenberg.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Golo Kronenberg, golo.kronenberg@pukzh.ch
This article was submitted to Emotion Regulation and Processing, a section of the journal Frontiers in Behavioral Neuroscience
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.